



Ref: Syn/CS/SE/PR/2023-24/Dec/01

**Syngene International Limited**  
Biocon SEZ, Biocon Park, Plot No. 2 & 3,  
Bommasandra Industrial Area, IV Phase,  
Jigani Link Road, Bengaluru 560099,  
Karnataka, India.  
T +91 80 6891 8000  
F +91 80 6891 8808  
CIN: L85110KA1993PLC014937  
[www.syngeneintl.com](http://www.syngeneintl.com)

December 1, 2023

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
<b>Scrip Code: 539268</b>	<b>Scrip Symbol: SYNGENE</b>

Dear Sir/Madam,

**Sub: Press Release.**

With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the press release titled **“Syngene concludes the acquisition of biologics manufacturing facility from Stelis Biopharma Ltd”**.

The above-mentioned press release will also be available on the website of the Company [www.syngeneintl.com](http://www.syngeneintl.com).

This is for your information and records.

Thanking You,

Yours faithfully,  
For **SYNGENE INTERNATIONAL LIMITED**

\_\_\_\_\_  
Priyadarshini Mahapatra  
**Company Secretary & Compliance Officer**

**Enclosed: Press Release**

**Press Release****Syngene concludes the acquisition of biologics manufacturing facility from Stelis Biopharma Ltd**

**Bangalore, December 1, 2023:** Syngene International today announced the conclusion of the acquisition of a multi-modal biologics manufacturing facility from Stelis Biopharma Ltd as announced on 4 July 2023. The acquisition of the 'Unit 3' biologics manufacturing facility was concluded at a revised gross value of Rs 617 crores adjusted from the earlier gross value of Rs 702 crores. The reduction in gross value reflects the retention of certain equipment not currently installed in the facility by Stelis Biopharma Ltd.

The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene. It also includes a commercial scale, high speed, fill-finish unit – an essential capability for drug product manufacturing.

The Unit has been acquired effective 1<sup>st</sup> December 2023 on payment of Rs 395 crores. The balance, subject to final adjustments, will be paid in December 2023 on completion of certain post-closing actions by Stelis Biopharma Ltd.

**About Syngene**

---

Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 6000 scientists offer both skills and the capacity to deliver great science, robust data security, and quality manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2 Mn sq. ft of specialist discovery, development and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit [www.syngeneintl.com](http://www.syngeneintl.com). For the Company's latest Environmental, Social, and Governance (ESG) report, visit <https://esgreport.syngeneintl.com/>.

## Contact details

Investor Contact	Media Contact
Krishnan G / Suruchi Daga P: +91 80 6891 9807 M: +919819992927 / 8800176009 Fax: +91 80 2852 3423 E: <a href="mailto:krishnan.g@syngeneintl.com">krishnan.g@syngeneintl.com</a> E: <a href="mailto:suruchi.daga@syngeneintl.com">suruchi.daga@syngeneintl.com</a>	Shotorupa Ghosh / Vijay Jeevanandham M: +91 8450977080/ +917760759922 Fax: +91 80 2852 3423 E: <a href="mailto:Shotorupa.ghosh@syngeneintl.com">Shotorupa.ghosh@syngeneintl.com</a> E: <a href="mailto:Vijay.jeevanandham@syngeneintl.com">Vijay.jeevanandham@syngeneintl.com</a>

**Disclaimer:** Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited (Syngene) and its associates. There can be no assurance that future developments affecting Syngene and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.